Sort   by:  
 Page size 
UnknownImpact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.
Not available
S-EPMC11868333 | biostudies-literature
UnknownRevised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.
Not available
S-EPMC12369922 | biostudies-literature
UnknownSurvival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.
Not available
S-EPMC12904337 | biostudies-literature
UnknownClinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.
Not available
S-EPMC11585342 | biostudies-literature
UnknownReal-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Not available
S-EPMC10969011 | biostudies-literature
UnknownTreatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.
Not available
S-EPMC10076530 | biostudies-literature
UnknownLow low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study.
Not available
S-EPMC7280258 | biostudies-literature
Sort   by:  
 Page size